专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07332523B2 TNP-470 polymer conjugates and use thereof 有权
标题翻译： TNP-470聚合物共轭物及其用途
公开(公告)号：US07332523B2
公开(公告)日：2008-02-19
申请号：US10511009
申请日：2003-04-10
申请人： Ronit Satchi-Fainaro , Judah Folkman
发明人： Ronit Satchi-Fainaro , Judah Folkman
IPC分类号： A61K31/336 , A61K38/04 , A61P9/00 , A61P35/04 , C07D407/08
CPC分类号： C08L53/00 , A61K47/58 , C07D303/22 , C08F220/56 , C08F220/58 , C08L2666/02
摘要： The present invention relates to conjugates of water-soluble polymers and o(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.
摘要翻译：本发明涉及水溶性聚合物和o（氯乙酰基 - 氨基甲酰基）烟曲霉醇（TNP-470）的缀合物，并将这些缀合物作为TNP-470的特异性细胞内载体用于肿瘤血管。本发明还涉及这些缀合物降低TNP-470的神经毒性的用途。优选地，聚合物的分子量在100Da至800kDa的范围内。更优选地，聚合物的分子量不大于60kDa。最优选地，聚合物的分子量在15kDa至40kDa的范围内。

2. 发明申请

US20080248030A1 Method of Treating Angiogenic Diseases 审中-公开
标题翻译：治疗血管生成疾病的方法
公开(公告)号：US20080248030A1
公开(公告)日：2008-10-09
申请号：US11883501
申请日：2006-02-02
申请人： Judah Folkman , Ronit Satchi-Fainaro
发明人： Judah Folkman , Ronit Satchi-Fainaro
IPC分类号： A61K39/395 , A61P9/00
CPC分类号： A61K39/3955 , A61K2300/00
摘要： The present invention relates to methods for treating cancer comprising administering an anti-VEGF (vascular endothelial growth factor) monoclonal antibody (e.g. Avastin) and a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-TNP-470 conjugate (e.g. Caplostatin) to a patient in need thereof.
摘要翻译：本发明涉及治疗癌症的方法，其包括施用抗VEGF（血管内皮生长因子）单克隆抗体（例如Avastin）和N-（2-羟丙基）甲基丙烯酰胺（HPMA）共聚物-TNP-470缀合物（例如卡洛斯汀）给有需要的患者。

3. 发明授权

US06949584B2 TNP-470 species, polymer conjugates and use thereof 有权
标题翻译： TNP-470物质，聚合物共轭物及其用途
公开(公告)号：US06949584B2
公开(公告)日：2005-09-27
申请号：US10783986
申请日：2004-02-19
申请人： Ronit Satchi-Fainaro , Judah Folkman
发明人： Ronit Satchi-Fainaro , Judah Folkman
IPC分类号： A61K31/785 , A61K39/395 , A61K45/00 , A61K47/48 , A61P9/00 , A61P35/00 , C07D303/22 , C07D407/08 , A61K31/336 , A61P35/04
CPC分类号： C08L53/00 , A61K47/58 , C07D303/22 , C08F220/56 , C08F220/58 , C08L2666/02
摘要： The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.
摘要翻译：本发明涉及水溶性聚合物和邻 - （氯乙酰基 - 氨基甲酰基）烟曲霉醇（TNP-470）的缀合物，并将这些缀合物作为TNP-470的特异性细胞内载体用于肿瘤血管。本发明还涉及这些缀合物降低TNP-470的神经毒性的用途。优选地，聚合物的分子量在100Da至800kDa的范围内。更优选地，聚合物的分子量不大于60kDa。最优选地，聚合物的分子量在15kDa至40kDa的范围内。

4. 发明申请

US20060020024A1 TNP-470 species, polymer conjugates and use thereof 审中-公开
标题翻译： TNP-470物质，聚合物共轭物及其用途
公开(公告)号：US20060020024A1
公开(公告)日：2006-01-26
申请号：US11185538
申请日：2005-07-20
申请人： Ronit Satchi-Fainaro , Judah Folkman
发明人： Ronit Satchi-Fainaro , Judah Folkman
IPC分类号： A61K31/336
CPC分类号： C08L53/00 , A61K47/58 , C07D303/22 , C08F220/56 , C08F220/58 , C08L2666/02
摘要： The present invention relates to conjugates of water-soluble polymers and o-(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.
摘要翻译：本发明涉及水溶性聚合物和邻 - （氯乙酰基 - 氨基甲酰基）烟曲霉醇（TNP-470）的缀合物，并将这些缀合物作为TNP-470的特异性细胞内载体用于肿瘤血管。本发明进一步涉及这些缀合物降低TNP-470的神经毒性的用途。优选地，聚合物的分子量在100Da至800kDa的范围内。更优选地，聚合物的分子量不大于60kDa。最优选地，聚合物的分子量在15kDa至40kDa的范围内。

5. 发明申请

US20050169881A1 Tnp-470 polymer conjugates and use thereof 有权
标题翻译： Tnp-470聚合物共轭物及其用途
公开(公告)号：US20050169881A1
公开(公告)日：2005-08-04
申请号：US10511009
申请日：2003-04-10
申请人： Ronit Satchi-Fainaro , Judah Folkman
发明人： Ronit Satchi-Fainaro , Judah Folkman
IPC分类号： A61K31/785 , A61K39/395 , A61K45/00 , A61K47/48 , A61P9/00 , A61P35/00 , C07D303/22
CPC分类号： C08L53/00 , A61K47/58 , C07D303/22 , C08F220/56 , C08F220/58 , C08L2666/02
摘要： The present invention relates to conjugates of water-soluble polymers and o(chloracetyl-carbamoyl) fumagillol (TNP-470) and use of those conjugates as specific intracellular carriers of the TNP-470 into tumor vessels. The present invention further relates to use of those conjugates to lower the neurotoxicity of TNP-470. Preferably, the polymer has a molecular weight in the range of 100 Da to 800 kDa. More preferably, the polymer has a molecular weight no greater than 60 kDa. Most preferably, the polymer has a molecular weight in the range of 15 kDa to 40 kDa.
摘要翻译：本发明涉及水溶性聚合物和o（氯乙酰基 - 氨基甲酰基）烟曲霉醇（TNP-470）的缀合物，并将这些缀合物作为TNP-470的特异性细胞内载体用于肿瘤血管。本发明还涉及这些缀合物降低TNP-470的神经毒性的用途。优选地，聚合物的分子量在100Da至800kDa的范围内。更优选地，聚合物的分子量不大于60kDa。最优选地，聚合物的分子量在15kDa至40kDa的范围内。

6. 发明授权

US08273383B2 Methods and compositions for treatment of preeclampsia 失效
标题翻译：用于治疗先兆子痫的方法和组合物
公开(公告)号：US08273383B2
公开(公告)日：2012-09-25
申请号：US11579777
申请日：2005-05-04
申请人： Judah Folkman , Raghu Kalluri
发明人： Judah Folkman , Raghu Kalluri
IPC分类号： A61K31/56
CPC分类号： A61K31/56
摘要： Methods and compositions for treating and/or preventing a pregnancy related disease or disorder are provided. The methods involve administration of 2-methoxyestradiol, or an analog thereof, to a subject. Also provided are methods for diagnosing or predicting a pregnancy related disease or disorder. The methods involve detection of 2-methoxyestradiol, or a precursor or metabolite thereof.
摘要翻译：提供了用于治疗和/或预防妊娠相关疾病或病症的方法和组合物。该方法涉及向受试者施用2-甲氧基雌二醇或其类似物。还提供了用于诊断或预测妊娠相关疾病或病症的方法。该方法涉及检测2-甲氧基雌二醇或其前体或代谢物。

7. 发明授权

US06638949B1 Prevention of adhesions and excessive scar formation using angiogenesis inhibitors 失效
标题翻译：使用血管生成抑制剂预防粘连和过度瘢痕形成
公开(公告)号：US06638949B1
公开(公告)日：2003-10-28
申请号：US09139375
申请日：1998-08-25
申请人： Judah Folkman , Harold Brem , H. Paul Ehrlich
发明人： Judah Folkman , Harold Brem , H. Paul Ehrlich
IPC分类号： A61K31445
CPC分类号： A61K38/484 , A61K38/4886
摘要： A method and compositions for inhibiting excessive scar formation and adhesions by administering to a patient in need thereof an effective amount of an angiogenesis inhibitor. In the preferred embodiment, the angiogenesis inhibitor is selective, such as a fumagillol derivative like 0-chloroacetylcarbamoyl-Fumagillol (TNP-470, TAP Pharmaceuticals), thalidomide, or a selective drug having more than one activity, such as minocycline or penicilliamine which also have antibiotic activity. Less selective compounds can also be used, such as the cytokine IL12. Patients to be treated include those having experienced trauma, surgical intervention, burns, and other types of injuries. The inhibitor is administered in an amount effective to decrease excessive scarring, defined as formation of high density tissue including cells and connective tissue, without preventing normal wound closure. The inhibitors can be administered systemically and/or locally or topically, as needed. For prevention of adhesions, the angiogenesis inhibitor would typically be applied at the time of surgery, preferably in a controlled release formulation and/or using barrier technology.
摘要翻译：一种用于通过向有需要的患者施用有效量的血管生成抑制剂来抑制过量瘢痕形成和粘连的方法和组合物。在优选的实施方案中，血管生成抑制剂是选择性的，例如如O-氯乙酰基氨基甲酰基 - 富马格隆（TNP-470，TAP Pharmaceuticals），沙利度胺或具有多于一种活性的选择性药物如米诺环素或青霉素的烟曲霉醇衍生物，有抗生素活性。也可以使用选择性较低的化合物，如细胞因子IL12。待治疗的患者包括经历创伤，手术干预，烧伤和其他类型损伤的患者。抑制剂以有效减少过度瘢痕形成的量给药，定义为包括细胞和结缔组织的高密度组织的形成，而不防止正常的伤口闭合。抑制剂可以根据需要系统地和/或局部或局部施用。为了防止粘连，通常在手术时应用血管生成抑制剂，优选在控制释放制剂中和/或使用屏障技术。

8. 发明申请

US20060258583A1 Anti-angiogenic peptides for treating or preventing endometriosis 有权
标题翻译：用于治疗或预防子宫内膜异位症的抗血管生成肽
公开(公告)号：US20060258583A1
公开(公告)日：2006-11-16
申请号：US11364887
申请日：2006-02-28
申请人： Judah Folkman , Kashi Javaherian , Christian Becker , Robert D'Amato
发明人： Judah Folkman , Kashi Javaherian , Christian Becker , Robert D'Amato
IPC分类号： A61K38/17 , A61K38/10
CPC分类号： A61K38/10 , A61K38/17 , C07K14/78
摘要： Provided herein are peptides and nucleic acids encoding the peptides, pharmaceutical compositions comprising the nucleic acids and proteins and methods for using the pharmaceuticals to treat or prevent endometriosis in a subject.
摘要翻译：本文提供了编码肽的肽和核酸，包含核酸和蛋白质的药物组合物以及使用该药物治疗或预防受试者子宫内膜异位症的方法。

9. 发明申请

US20090209497A1 METHOD OF TREATING LYMPHANGIOLEIOMYOMATOSIS (LAM) 审中-公开
标题翻译：治疗淋巴细胞白血病的方法（LAM）
公开(公告)号：US20090209497A1
公开(公告)日：2009-08-20
申请号：US11913709
申请日：2006-05-16
申请人： Judah Folkman , George Abrams , Marsha A. Moses
发明人： Judah Folkman , George Abrams , Marsha A. Moses
IPC分类号： A61K31/65 , A61P11/00
CPC分类号： A61K31/65
摘要： The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored by measuring MMP levels. Reduction in MMP levels indicates that the treatment is effective.
摘要翻译：本发明提供了在有需要的人类受试者中治疗淋巴管平滑肌瘤病（LAM）的方法。该方法包括向受试者施用有效量的多西环素或其盐。本发明还提供了用于监测治疗功效的方法。通过测量MMP水平监测治疗效果。 MMP水平的降低表明治疗有效。

10. 发明申请

US20060251699A1 Anti-angiogenic peptides from the N-terminus of endostatin 有权
公开(公告)号：US20060251699A1
公开(公告)日：2006-11-09
申请号：US11364855
申请日：2006-02-28
申请人： Judah Folkman , Kashi Javaherian , Robert Sjin
发明人： Judah Folkman , Kashi Javaherian , Robert Sjin
IPC分类号： A61K38/16 , A61K38/10 , C07K14/47 , C07K7/08 , C07H21/04 , C12P21/06
CPC分类号： C07K14/78 , A61K38/00
摘要： Provided herein are anti-angiogenic comprising the N-terminal end of endostatin, nucleic acids encoding the same, pharmaceutical preparations comprising an effective amount of the peptide and nucleic acids and use of the pharmaceuticals in treating or preventing diseases or conditions associated with undesirable angiogenesis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式